Corvus Pharmaceuticals Inc (CRVS) Expected to Announce Earnings of -$0.46 Per Share
Analysts predict that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will report earnings of ($0.46) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.45). Corvus Pharmaceuticals reported earnings of ($0.62) per share during the same quarter last year, which suggests a positive year over year growth rate of 25.8%. The firm is scheduled to report its next earnings report on Thursday, November 1st.
On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.02) to ($1.94). For the next financial year, analysts forecast that the business will post earnings of ($1.79) per share, with EPS estimates ranging from ($1.88) to ($1.70). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, August 2nd. The company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.24.
Several hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 48.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after acquiring an additional 8,400 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Corvus Pharmaceuticals by 35.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after acquiring an additional 9,782 shares during the period. Deutsche Bank AG increased its holdings in shares of Corvus Pharmaceuticals by 118.1% in the 4th quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock worth $196,000 after acquiring an additional 10,320 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock worth $236,000 after acquiring an additional 12,119 shares during the period. Finally, Rhumbline Advisers acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth about $147,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:CRVS traded down $0.05 on Friday, reaching $9.37. 31,726 shares of the company’s stock were exchanged, compared to its average volume of 70,484. Corvus Pharmaceuticals has a fifty-two week low of $7.42 and a fifty-two week high of $17.64.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Story: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.